Describing a Retrospective Approach: Liquid Biopsy CDx Development & Submission for HER2-mut NSCLC

Time: 5:00 pm
day: Day One Track B PM 2


  • Elucidating how liquid biopsy tests allow NSCLC patients access to HER2 mutation results who otherwise would not be tested
  • Describing the validation study design of Guardant360 CDx test in detection of HER2 mutation in plasma obtained from patients with NSCLC
  • Raising challenges and solutions in retrospective CDx development